A Phase Ii Randomized Study of Bortezomib/Dexamethasone (bort/dex) with or Without Elotuzumab (elo) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (rr Mm) (Ca204-009).
JOURNAL OF CLINICAL ONCOLOGY（2012）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要